GRI GRI BIOWatchlist
About GRI BIO Company
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersNexImmune (NASDAQ:NEXI) stock moved upwards by 343.1% to $10.99 during Friday's pre-market session. The market value of their outstanding shares is at $11.6 million. Altimmune (NASDAQ:ALT) stoc
GRI Bio Secures FDA Clearance for Investigational New Drug Application for Pulmonary Fibrosis Treatment
GRI Bio (GRI) said Monday that the US Food and Drug Administration has cleared its investigational new drug application for GRI-0621 for the treatment of idiopathic pulmonary fibrosis.
GRI Bio Says FDA Clears IND For GRI-0621 For Treatment Of IPF; Stock Up 19%